Recombinant Therapy

Adenovirus-Based Therapy Yields Positive Results In Dendritic Cells

Published in Gene Therapy Weekly, February 7th, 2002

by Sonia Nichols, senior medical writer - Recombinant adenovirus-based therapies may contain certain properties that make them advantageous for dendritic cell differentiation, researchers say.

The collaborative team comprising investigators at the U.S. National Cancer Institute (NCI) in Frederick, Maryland, and the Cleveland Clinic Foundation in Cleveland, Ohio, was able to get human CD14{{+}} monocytes to differentiate after being infected by adenovirus type 5 viral vectors.

"Under serum-free conditions, this resulted in differentiation of a majority of cells toward a dendritic cell phenotype within 36 to 48 hours, without the need for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-02-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry